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ABSTRACT
The prevalence of type 2 diabetes (T2D) has increased rapidly. Adopting a heathy diet is suggested as one of the eﬀective behaviors to prevent
or delay onset of T2D. Dairy consumption has been recommended as part of a healthy diet, but there remains uncertainty in both the scientiﬁc
community and the public about the eﬀect of diﬀerent dairy products on T2D risk. In a recent workshop, the evidence on dairy products and
T2D risk was presented and discussed by a group of experts. The main conclusions from the workshop are presented in this position paper and
are as follows. 1) Available evidence from large prospective cohort studies and limited randomized controlled trials (RCTs) suggests that total dairy
consumption has a neutral or moderately beneﬁcial eﬀect on T2D risk. 2) Increasing evidence from prospective cohort studies indicates that yogurt
ismost strongly associatedwith a lower T2D risk, but evidence fromRCTs is scarce. 3) Fatty acids fromdairy (medium-chain, odd, and very long-chain
SFAs as well as trans-palmitoleic acid) are associated with lower T2D risk and improved metabolic health, but more research is needed on studies
that explore cause and eﬀect relations to exclude the possibility that the dairy fatty acids simply serve as markers of overall dairy consumption.
4) The food matrix can be a stronger determinant of health eﬀects than SFA content. This review further identiﬁes research gaps in the existing
knowledge and highlights key research questions that need to be addressed to better understand the impact of dairy consumption on future T2D
risk. Adv Nutr 2019;10:1066–1075.
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Introduction
The prevalence of diabetes has increased rapidly in recent
times, and globally 425 million people were affected by
diabetes in 2017, mainly type 2 diabetes (T2D), which
comprises ∼91% of all cases of diabetes (1). It is expected
that the worldwide number of people with T2D will rise
to 629 million by 2045 and a further 352 million people
with impaired glucose tolerance will have a high risk
of developing diabetes (1). Diabetes is a serious medical
condition that often requires the use of oral antidiabetic
medication or insulin injections tomaintain glycemic control
(2). In 2017, the global healthcare cost of diabetes, including
treatment and related complications, reached US$850 billion
(1). Lifestyle interventions, particularly reducing sedentary
behavior, increasing exercise, energy intake restriction to
promote weight loss, and adopting a healthy diet, are usually
effective for reducing insulin resistance, and may partially
restore pancreatic β-cell function, thereby reducing the need
for glucose-lowering medication, and preventing or delaying
the onset of T2D (3–9). The pathophysiology of T2D is
complex and not the same for each individual, but insulin
resistance and β-cell dysfunction are key factors in the
development of T2D. It is well established that adipose
tissue dysfunction (impaired adipose tissue expandability,
adipocyte hypertrophy, altered lipid metabolism, and local
inflammation), whichmay partly be explained by altered adi-
pose tissue oxygenation, is a central player in obesity-related
insulin resistance (10–12). Abdominal fat accumulation and
low lean bodymass are associated with insulin resistance and
increased T2D risk, whereas lower-body fat storage seems
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protective against the development of T2D and cardiovascu-
lar disease, when adjusted for total adipose tissue mass (13–
15). Evidence from a recent meta-analysis of randomized
controlled trials (RCTs) suggested dairy products may have
modest benefits in assisting weight loss in short-term or
energy-restricted RCTs (16), with some specific evidence
showing that yogurt consumption is associated with a lower
risk of obesity, lower risk of increased body weight, and
lower risk of elevated waist circumference (17). In addition,
a recent meta-analysis of RCTs indicated that increased dairy
consumption as part of energy-restricted diets resulted in
greater loss in body weight and fat mass, while preventing
excessive loss of lean body mass in 18- to 50-y-old adults
(18). Furthermore, as one of the important food groups in
guidelines for a healthy diet (19, 20), there are components
in dairy which have been suggested to be beneficial for
T2D, such as flavonoids, calcium, medium-chain and odd-
chain saturated fats, unsaturated fats, branched-chain amino
acids (BCAAs), trans-palmitoleic acid (trans 16:1n–7), pro-
biotics, and phylloquinone (vitamin K-1) andmenaquinones
(vitamin K-2) (21, 22). However, dairy products also contain
saturated fats, trans fats, and sodium,which could be harmful
for T2D (23–26). In addition, the recent study of Liu et al.
(27) investigated the association between dietary SFAs and
T2D risk by following 37,421 participants for 10 y, and found
milk and milk products and butter-derived SFAs were not
statistically significantly associated with T2D risk, except for
cheese-derived SFAs which were associated with a lower T2D
risk (HR 0.90; 95% CI: 0.83, 0.98). Furthermore, the recent
review of Thorning et al. (28) indicated that cheese intake
generally results in a lower LDL-cholesterol response than
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that from the same amount of dairy fat as butter, which is
suggestive that fat consumed in isolation (butter) is more
bioavailable than fat that is carried in the cheese matrix (29).
US dietary guidelines recommend daily consumption of
3 cups of fat-free or low-fat (1%) milk and milk products
for individuals aged ≥9 y (30). In line with the United
States, low-fat and low-sugar dairy products have been
recommended as part of the Eatwell Guide in the United
Kingdom, althoughwithout quantity recommendations (31).
However, very little evidence exists on the adverse impact
of high-fat compared with low-fat dairy consumption on
T2D risk. The most recent meta-analysis of 13 prospective
cohort studies found no association between high-fat dairy
and T2D risk (32). In addition, although sugar improves
the palatability of dairy foods like yogurt (33), there is
little evidence on whether there is any differential effect of
sweetened and unsweetened or artificially sweetened yogurt
on human health.
The current article is based on presentations, discussions,
and conclusions from a workshop on the effect of dairy foods
on the risk of T2D. The closed consensus workshop of invited
scientists was held at Wageningen University (Wageningen,
Netherlands) on 20–21 November, 2017. A total of 8 experts
(DIG, AA, SJLB, GHG, MK, AM, HP, SSS-M) were selected
based on their previous published work on dairy products
and diabetes-related topics, representing different scientific
areas related to dairy foods and health. Before the workshop,
each expert was asked to prepare a presentation summarizing
the evidence in his/her area of expertise. Each presentation
was challenged during an extensive discussion.
Evidence from Prospective Cohort Studies on
Dairy Products and T2D Risk
A number of systematic reviews and meta-analyses (32, 34–
37) have published evidence on the association between dairy
products and T2D. Themost recentmeta-analysis of Gijsbers
et al. (32) in 2016 performed a dose–response meta-analysis
to quantify the associations of incident T2D with total
dairy and types of dairy consumption at different amountsof
intake. The meta-analyses of Gao et al. (35) and Aune et al.
(34) were both dose–response meta-analyses and of similar
design to Gijsbers et al. (32), and will therefore be discussed
in the following sections. Using similar search strategies and
inclusion and exclusion criteria for study selection asGijsbers
et al. (32), 4 new prospective cohort studies (38–41) were
identified with data on dairy and incident diabetes. All the
cohort studies mentioned in the meta-analyses of Gijsbers et
al. (32), Aune et al. (34), Gao et al. (35), and more recently
published studies (38–41) are summarized in Supplemental
Table 1.
Total dairy
Previous meta-analyses by Gao et al. (35) and Aune et al.
(34) in 2013 both reported a significant inverse associa-
tion between total dairy consumption and T2D risk. The
summary RRs were 0.93 (95% CI: 0.87, 0.99) per 400 g/d
Dairy products and type 2 diabetes 1067
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and 0.94 (95% CI: 0.91, 0.97) per 200 g/d for Aune et al.
(34) and Gao et al. (35), respectively. The meta-analysis by
Gijsbers et al. (32) summarized data from 16 studies and
the main finding was a linear inverse association for total
dairy intake, with a 3% lower T2D risk per 200 g/d higher
intake (RR: 0.97; 95% CI: 0.95, 1.00), which was in line with
findings of earlier studies (34, 35). Most studies included in
these meta-analyses were from Europe and America (32, 34,
35). In subgroup analyses, a stronger inverse association was
found in Aisan populations (RR: 0.85, 95% CI: 0.65, 1.12),
but no association in European populations (32). The results
of a recently published study based on data of a Chinese
prospective cohort (39) were consistent with previous meta-
analyses (32, 34, 35). In the Chinese cohort study, a total
of 45,411 Chinese men and women were followed for 12 y
(39) and total dairy was associated with a significantly lower
T2D risk, with high dairy consumers having a significant 10%
reduction in T2D risk compared with low consumers (39).
Another 3 recent studies (38, 40, 41) found no association
between total dairy consumption and T2D risk, but these
studies had relatively small sample sizes ranging from 1867
to 2974 subjects. By adding 4 new studies (38–41) into the
most recent meta-analysis of Gijsbers et al. (32), the updated
results of Soedamah-Muthu and de Goede (42) showed a
similar result, that total dairy (per 200 g/d) was borderline
significantly associated with a 3% lower T2D risk (RR: 0.97;
95% CI: 0.95, 1.00), although with significant heterogeneity
existing between studies (I2 = 62.8%).
Liquid milk
For the associations between liquid milk consumption and
T2D risk, the most up-to-date meta-analysis by Gijsbers
et al. (32) summarized 11 studies and showed that total
milk consumption was not associated with T2D risk (RR:
0.97; 95% CI: 0.93, 1.02—per 200 g/d), which is in line
with previous meta-analyses (34, 35). Recently published
prospective cohort studies (38, 40, 41) have also confirmed
a null association between milk consumption and T2D. On
the contrary, a recent Chinese prospective cohort study (39)
followed 45,411 participants for 12 y and found that daily
intake of milk was associated with a lower T2D risk (HR:
0.88; 95% CI: 0.81, 0.96—comparing daily drinkers with
nondrinkers; P for trend = 0.01), although the majority of
participants (67.4%) never or hardly drank milk and only
15% of participants were daily milk consumers. This inverse
association was in line with the subgroup analysis by Gijsbers
et al. (32), which also indicated an inverse association
of milk consumption and T2D risk (RR: 0.87; 95% CI:
0.72, 1.05—per 200 g/d) in Asian populations. In addition,
Bergholdt et al. (43) addressed the question of whether there
could be a causal association between milk consumption
and T2D by milk intake observationally and genetically
via lactase persistence, using a Mendelian Randomization
design in 97,811 subjects of the Danish general population.
This found that high milk intake was not associated with
T2D risk.
Fermented dairy
Fermented dairy products are the milk products prepared
by lactic acid fermentation or a combination of this and
yeast fermentation, mainly consisting of yogurt and cheese
(44). For yogurt, the most recent meta-analysis by Gijsbers
et al. (32) reported a nonlinear inverse association between
yogurt consumption and T2D risk at 80 g/d (RR: 0.86;
95% CI: 0.83, 0.90—compared with 0 g/d), although with
significant heterogeneity existing between studies (I2 = 73%),
which was consistent with previous meta-analyses reporting
yogurt consumption to be inversely associated with lower
T2D risk (34, 35). Evidence of the association between yogurt
consumption and T2D risk was only available in 2 (38, 40)
out of the 4 recently published prospective cohort studies
(38–41), and they reported neutral associations between
yogurt intake and T2D risk; however, these 2 studies (38, 40)
were based on cohorts with small sample sizes (1867–2974
participants) compared with the meta-analysis by Gijsbers
et al. (32) (22 cohort studies, 579,832 participants). The
study by Soedamah-Muthu and de Goede (42) updated the
meta-analysis of Gijsbers et al. (32) by adding the 2 new
studies (38, 40) and found a similar result: that of a nonlinear
inverse significant association of yogurt consumption with
T2D risk (RR: 0.86; 95% CI: 0.83, 0.90; I2 = 69%, at 80 g/d
compared with 0 g/d). For the associations between yogurt
of different fat contents and T2D risk, to our knowledge,
evidence is only available from the PREDIMED study (45,
46), which followed 3349 individuals free of T2D but at high
cardiovascular disease risk for 4 y and found both whole-fat
yogurt and low-fat yogurt to be associated with a lower T2D
risk.
An inverse association between cheese consumption and
T2D risk was found by the earlier meta-analyses by Aune
et al. (34) and Gao et al. (35) with pooled RRs of 0.92
per 50 g/d (95% CI: 0.86, 0.99; 8 studies; I2 = 0%) and
0.80 per 30 g/d (95% CI: 0.69, 0.93; 7 studies; I2 = 59%),
respectively. The more recent meta-analysis by Gijsbers et al.
(32) reported a neutral association between cheese intake and
T2D risk (RR: 1.00 per 10 g/d; 95% CI: 0.99, 1.02; 12 studies),
although significant heterogeneity was present (I2 = 62%).
The findings of 2 new published cohort studies (40, 41) were
in accordance with Gijsbers et al. (32), showing that cheese
intake was not associated with T2D risk.
Butter
There has been an increasing controversy around the effect
of butter on human health (47), because butter has the
highest fat and saturated fats concentrations of all dairy
products. The meta-analyses by Aune et al. (34), Gao et al.
(35), and Gijsbers et al. (32) did not analyze data separately
for butter. Interestingly, a recent meta-analysis by Pimpin
et al. (47) summarized 4 studies (46, 48–50) and reported
that butter (per 14 g/d) consumption tended to be inversely
associated with a lower risk of T2D (RR: 0.96; 95% CI: 0.93,
0.99). Furthermore, Mozaffarian (51) and Pimpin et al. (47)
indicated the existence of potential publication bias for the
1068 Guo et al.
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relations between butter intake and T2D risk. Therefore, the
evidence on butter from cohort studies overall suggests, if
anything, a slightly inverse association with T2D risk, but
more studies are needed.
Cream and ice cream
There are a limited number of cohort studies which have
investigated the associations between cream or ice cream
intake andT2D risk. Threemeta-analyses (32, 34, 35) showed
consistent results that cream was not associated with T2D
risk and there were no significant heterogeneities existing
between studies. Ice cream was significantly associated with
lower T2D risk in 2 meta-analyses (32, 34) and significant
heterogeneity (I2 = 86%) was present in the study of Gijsbers
et al. (32) but not in that of Aune et al. (34). There has been no
further updated evidence on the association between cream
or ice cream and T2D risk.
Dairy fat content
For high-fat and low-fat dairy, the meta-analysis by Gijsbers
et al. (32) summarized 13 studies and reported a borderline
significant linear inverse association between low-fat dairy
and T2D (RR: 0.96; 95%CI: 0.92, 1.00; P= 0.072; I2 = 68%—
per 200 g/d) and no association between high-fat dairy and
T2D (RR: 0.98; 95% CI: 0.93, 1.04; P = 0.52; I2 = 52%—
per 200 g/d). The results by Gijsbers et al. (32) agreed with
earlier meta-analyses by Gao et al. (35) and Aune et al. (34),
which both also reported low-fat but not high-fat dairy to
be inversely associated with T2D risk. Although the recent
prospective cohort study of Brouwer-Brolsma et al. (40),
involving 2974 participants with a mean follow-up of 9.5 y,
reported no association between both high-fat and low-fat
dairy consumption and T2D risk, Hruby et al. (38) reported
that greater high-fat dairy consumption was associated with
70% lower T2D risk in 925 subjects with prediabetes. The
other 2 recently published prospective cohort studies (39,
41) did not separate high-fat or low-fat dairy from total
dairy consumption, which precludes drawing conclusions
concerning differential associations for low-fat compared
with high-fat dairy. Recently, the study of Soedamah-Muthu
and de Goede (42) pooled the data of the new studies (38,
40) with the previous meta-analysis of Gijsbers et al. (32) and
reported a similar result: that low-fat dairy was borderline
significantly associated with a 4% lower T2D risk (RR: 0.96;
95%: 0.92, 1.00; I2 = 60.3%).
Prediabetes
For incident prediabetes, the Framingham Heart Study
Offspring Cohort study (38) found an inverse association
between total dairy intake and incident prediabetes, with
higher total dairy intake associated with a 37% lower risk
of incident prediabetes (HR: 0.63; 95% CI: 0.49, 0.80),
which may indicate early-phase effects of dairy consumption
potentially delaying and/or preventing the onset of T2D.
Furthermore, there are a few cross-sectional studies (52, 53)
which also studied the associations between dairy consump-
tion and prediabetes. The study by Eussen et al. (53) found
that high consumption of skimmed dairy and fermented
dairy was associated with a lower risk of impaired glucose
metabolism, whereas high intake of high-fat dairy was not
related to impaired glucose metabolism. The findings of
Brouwer-Brolsma et al. (52) were in line with those of Eussen
et al. (53), with similar inverse associations of skimmed dairy
and fermented dairy with prediabetes, although positive
associations were observed for high-fat and nonfermented
dairy consumption. However, a limitation of these studies
was a nonconsistent definition of prediabetes. For example,
prediabetes was defined as “the first occurrence of fasting
plasma glucose ≥5.6 to <7.0 mmol/L” and “fasting plasma
glucose between 5.6 and 6.9 mmol/L or HbA1c% [glycated
hemoglobin percentage] of 5.7–6.4%” in the studies of Hruby
et al. (38) and Brouwer-Brolsma et al. (40), respectively.
Evidence from RCTs on Dairy Products and T2D
Risk
There are only 2 reviews (23, 54) and 2 meta-analyses
(55, 56) that have been published on RCT-based evidence
concerning effects of dairy consumption on T2D risk. An
earlier review (57) highlighted that investigating the effect of
dairy consumption on health is highly challenging, because
only evidence of dairy consumption and biomarkers of T2D
is available, with no data on hard endpoints of incident T2D.
It is difficult to determine the effect of dairy consumption
on T2D risk from the available RCT-based evidence owing
to variations in study design, sample size, and types of
dairy consumption. In their meta-analysis of RCTs, Benatar
et al. (55) investigated the effects of increased dairy food
consumption on cardiometabolic risk factors by including
data from 20 studies. Thismeta-analysis showed a high-dairy
diet may lead to a moderately improved HOMA-IR (mean
−0.94; range −1.93 to 0.04 units; P = 0.06), albeit with
significant heterogeneity existing between studies (I2 = 92%).
Furthermore, a recent meta-analysis of O’Connor et al. (56)
with 38 studies showed a higher dairy intake was positively
associated with fasting glucose (mean 0.07 mmol/L; 95%
CI: 0.01, 0.12 mmol/L; I2 = 23%; P = 0.01) and negatively
associated with HbA1c (mean −0.09%; 95% CI: −0.09%,
−0.03%; I2 = 0%; P = 0.005), whereas the higher dairy
consumption was not associated with fasting insulin or
HOMA-IR. Both meta-analyses of Benatar et al. (55) and
O’Connor et al. (56) reported that most RCTs were small and
the quality of evidence was low.
In addition, the systematic review of Turner et al. (54)
investigated 10 weight-stable interventions that examined
the effect of an increased intake of dairy products or dairy-
derived supplements on glucose metabolism and insulin
sensitivity, and found the impact to be dependent on the
duration of the interventions. Specifically, studies of <8 wk
showed no significant changes in insulin sensitivity, whereas
studies between 12 and 24 wk resulted in a favorable effect
of higher dairy intake on insulin sensitivity. Results for
studies with a longer intervention time of 6 mo were mixed.
Of particular importance, few studies reported effects of
dairy on a dynamic measure of glucose tolerance, such as
Dairy products and type 2 diabetes 1069
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those based on an oral-glucose-tolerance test (OGTT) or
intravenous-glucose-tolerance test, and those that did tended
to report null effects. Thus, conclusions on the effect of dairy
consumption on glucose metabolism and insulin sensitivity
need confirmation in large RCTs with more subjects and
longer intervention times.
Low-fat dairy has been recommended in several dietary
guidelines (19, 58). However, a comprehensive review of
Drouin-Chartier et al. (59) assessed evidence from RCTs and
reported noharmful effect of dairy consumption, irrespective
of fat content, on different aspects of cardiometabolic risk.
More recently, Engel et al. (60) conducted a 3-wk crossover
dietary intervention in 18 healthy adults to compare the effect
of whole milk with skimmed milk consumption. The results
showed that ingestion of 0.5 L/d wholemilk did not adversely
affect fasting glucose or insulin compared with skimmed
milk. Thus, the authors concluded that whole milk might
be considered part of a healthy diet for the general healthy
population. Furthermore, only 1 RCT (61) has compared the
effects of regular-fat cheese (25% fat of Riberhus and 32%
fat of Sharp Cheddar) with an equal amount of reduced-fat
cheese (13% fat of Riberhus and 16% fat of Sharp Cheddar)
and it found no differential impact on fasting glucose, fasting
insulin, and HOMA-IR.
A major limitation of the literature in this field is that
most studies were not designed to test the impact of dairy
products on glucose homeostasis, which is reflected in the
fact that comprehensive measures of glucose homeostasis
were commonly not obtained. Also, the nature of the control
treatment chosen in RCTs appears critical, because it likely
influences the effects found. If one were to, for example,
comparemilk with a sugary drink, it would result in different
findings than if one were to compare milk with tea or
water. Another limitation is that most studies only used
fluid milk, most commonly skimmed or low-fat milk, in
their dairy diets, i.e., high-fat and/or fermented dairy foods
were not commonly tested, or accounted for only a small
portion of the administered dairy products. A recent meta-
analysis of Barengolts et al. (62) including 9 RCTs and only
472 participants showed no beneficial effects of consuming
probiotic yogurt compared with conventional yogurt for
improving glucose control in patients with T2D or obesity.
This study (62) highlighted the limitation of small RCTs and
short-term studies. Furthermore, almost noRCTs specifically
tested the impact of cheese or yogurt on glucose homeostasis
for general healthy populations. Although yogurt and/or
cheese were included as part of the overall dairy intervention
in some studies (63–69), the amount of dairy consumed as
cheese or yogurt was usually small or not specified, which
precludes conclusions about the specific impacts of yogurt or
cheese on glucose homeostasis from these studies.
Summary of Evidence from Prospective Cohort
Studies and RCTs
Evidence from prospective cohort studies and RCTs sug-
gests that dairy consumption has a neutral or moderately
beneficial effect on glucose homeostasis and T2D risk.
One advantage of the prospective cohort studies is that
they can show the long-term association between dairy
consumption and a disease outcome, such as incident T2D
(70). However, analyses of prospective cohort studies have
important limitations. For example, residual confounding
can never be ruled out from prospective cohort studies,
which may have led to the inconsistent findings in studies
on dairy consumption andT2D. Furthermore, the definitions
of the dairy foods consumed vary substantially across
different cohort studies. For example, high-fat dairy in a
study by Montonen et al. (50) included cheese, cream, ice
cream, and yogurt, whereas high-fat dairy in a study by
Soedamah-Muthu et al. (71) was defined as full-fat cheese,
yogurt, milk puddings, wholemilk, and Channel Islandmilk.
Therefore, additional epidemiological studies should assess
the associations between different well-defined types of dairy
consumption and T2D risk. In addition, inmost longitudinal
cohort studies, dairy consumption was only reported at
baseline but not during the follow-up period. Thus, it is
unknown whether or not the conclusions are affected by
dietary changes with time.
Evidence from RCTs on the impact of dairy products on
T2D risk largely suggests a null effect or a relatively small
inverse effect. Although RCTs could provide strong evidence
on a direct clinically relevant measure, i.e., glucose tolerance,
few RCTs included suchmeasures. The few RCTs (66, 72–76)
that included a mixed-meal test or OGTT suggest no effect
of dairy on glucose tolerance. The available studies differed
substantially in terms of types of dairy foods studied, the
duration of the intervention period, control diet, and subject
characteristics. Most studies have been conducted in over-
weight or obese subjects, with few studies in subjects with
normal weight. In addition, few intervention studies have
been designed to evaluate the effect of different types of dairy
foods or fat content of dairy foods on T2D risk, and there
was only 1 RCT (61) which compared the effects on T2D
risk of low-fat and full-fat cheese consumption. In terms of
investigating causal effects, evidence from suitably designed
RCTs could provide more evidence on the mechanisms
involved in the associations between dairy consumption and
T2D development. However, evidence from long-term RCTs
investigating the effect of dairy consumption on T2D risk is
very limited. Furthermore, most RCTs have been designed
to test the effect of dairy consumption on weight reduction
for overweight or obese subjects, but few studies have been
designed to specifically test the impact of dairy foods on
glucose homeostasis. Therefore, larger and more long-term
RCTs are needed to verify the effect of different types of dairy
consumption on T2D risk.
Lastly, the evidence from prospective cohort studies,
which showed higher intake of subtypes of dairy (e.g.,
yogurt, low-fat dairy) to be associated with lower T2D risk,
needs to be combined with evidence from RCTs wherein
the types and doses of dairy products can be regulated
and also mechanisms can be investigated. For example,
it is suggested that probiotic yogurt consumption may
improve glycemic control in T2D subjects (77–80), which
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may indicate that yogurt containing certain bacterial species
may have a beneficial effect on glucose homeostasis and T2D
risk. Therefore, the effect of yogurt and any differential effects
of yogurts with different fat, sugar, or protein contents or
different bacteria species on T2D risk should be investigated
by both prospective cohort studies and RCTs.
Dairy and T2D: Potential Mechanisms
The development of T2D is heavily influenced by obesity
and lifestyle. Specifically, abdominal fat deposition and low
lean body mass contribute to insulin resistance and increase
T2D risk, whereas fat stored in the lower part of the body
(gynoid and leg fat) seemsprotective against the development
of cardiometabolic diseases when total adipose tissue mass
is the same (13–15). This may reflect a high propensity to
accumulate fat in all subcutaneous adipose where it may have
a less detrimental effect on insulin sensitivity than visceral
fat accumulation (13). A recent meta-analysis of 24 RCTs
(18) reported that increased dairy food intake as part of
energy-restricted diets gave rise to greater loss in bodyweight
and fat mass, while moderating lean mass loss in 18- to
50-y-old adults. Therefore, dairy consumption may play a
beneficial role in managing body composition, which may
have a favorable effect on reducing T2D risk. The potential
mechanisms of the beneficial effects of dairy consumption on
body compositionmay be due to milk consumption assisting
appetite control in the context of energy-restricted diets (81).
In addition, the dairy protein–derived BCAAs have been
suggested to enhance muscle protein synthesis, lean body
mass, and skeletal muscle metabolic function (82).
SFAs have been considered a risk factor for T2D and
insulin resistance (83); however, the findings on the asso-
ciation between SFAs and T2D or insulin resistance are
mixed (24). Previous studies (28, 84) demonstrated that
individual SFAs have differential effects on T2D risk, and
suggested that the whole foods (i.e., food matrix) in which
SFAs exist can be a stronger determinant of health effects
than the total SFA content itself (28, 29). Several plasma
phospholipid even-chain SFAs [myristic acid (14:0), palmitic
acid (16:0), and stearic acid (18:0)] were reported to be
associated with higher T2D risk (85). In contrast, the odd-
chain SFAs pentadecanoic acid (15:0) and heptadecanoic acid
(17:0) are markers for intake of dairy fat (86). For these,
it has been shown that their proportions in erythrocyte
membranes are inversely associated with T2D risk (87).
An inverse association has also been reported for the
proportions of pentadecanoic and heptadecanoic acids in
plasma phospholipids with fasting insulin and glucose (88,
89). Furthermore, 2 studies by Mozaffarian et al. (90, 91)
have shown an inverse association between the concentration
of trans-palmitoleic acid in plasma phospholipids and risk
of T2D, with the suggestion that trans-palmitoleic acid was
of dietary origin, mainly from dairy foods. However, the
concentration of trans-palmitoleic acid in dairy fat is low
(92) and it remains a key question as to whether this fatty
acid has a functional role in reducing T2D risk or whether
it is merely a marker of dairy consumption. In addition,
a cross-sectional investigation in 17 men and women with
nonalcoholic fatty liver disease and 15 controls matched for
age and BMI indicated dairy fat improves glucose tolerance,
possibly via a mechanism involving improved hepatic and
systemic insulin sensitivity and reduced liver fat (93).
Other components of dairy foods may also have a part
to play, such as calcium, which has been recognized to
have an antiobesity bioactivity, and there is also good
evidence of a postprandial insulinotropic effect of milk
proteins, in particular whey proteins (94). Evidence from
RCTs suggests dairy proteins have more potent effects on
insulin and incretin secretion than do other animal proteins
(95). Although Rideout et al. (69) showed improved insulin
sensitivity in high compared with low dairy consumers over
a 12-mo RCT period, there is an urgent need for more long-
term studies on the effects of dairy on insulin sensitivity.
Systematic reviews indicate that yogurt has a greater
impact on metabolic health than nonfermented dairy but
the underlying mechanisms remain unknown (96). Yogurt
is a nutrient-dense dairy food that may help to reduce
weight gain and prevent T2D by contributing to intakes
of protein, calcium, bioactive lipids, and several other
micronutrients. It has also been suggested that fermentation
with bacterial strains produces bioactive peptides that may
contribute to the beneficial effect of yogurt on metabolic
health (96). Furthermore, fermented dairy may promote
gut microbial population shifts (21). It is of interest that
Veiga et al. (97) showed that consumption of a fermented
milk product (containing Bifidobacterium animalis subsp.
lactis) stimulated colonic production of acetate, butyrate, and
total SCFAs. Robertson et al. (98) showed that increased
production of SCFAs arising from dietary resistant starch
was associated with improved insulin sensitivity, and based
on a population study, Layden et al. (99) reported that
the concentration of serum acetate, but not propionate or
butyrate, was negatively associatedwith fasting serum insulin
and 2-h insulin concentrations after anOGTT. Serum acetate
was also inversely associated with visceral adipose tissue.
Recent reviews on the links between intestinal SCFAs and
diet and health (100–102) concluded that although many
biological effects seem to be mediated by SCFAs, more
conclusive proof is needed, particularly involving human
trials.
Current Status of Research in Relation to
Prevention, Prediabetes, and T2D
Several large prospective cohort studies have shown amodest
inverse relation between dairy consumption and T2D risk,
especially for yogurt. Many different types of dairy foods
and subtypes of dairy have been included in cohort studies.
There was considerable between-study heterogeneity, which
may be due to differences in country, study populations,
types of products, and definitions of dairy, and variations
in intake, which makes drawing firm conclusions difficult.
Evidence from RCTs on each different type of dairy products
and effects on T2D outcomes is lacking. The most available
acute and long-term RCTs have focused on overweight
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or obese populations, whereas studies on subjects with
prediabetes would be beneficial to assess the potential of
dairy foods to prevent or delay the manifestation of T2D.
Furthermore, T2D has a complex pathophysiology and
multiple treatments, being responsive to lifestyle changes.
The metabolic response to certain dietary interventions
such as dairy may vary between individuals, for example,
the glycemic response to a dietary intervention seems to
be at least partly determined by the specific metabolic
status (insulin resistance in particular) of an individual
(103–105). Importantly, most human exercise and dietary
intervention studies often lack a detailed phenotyping of
study participants, or are too small to conduct subgroup
analyses that would provide insight into interindividual
variability in response. Therefore, deep clinical/metabolic
phenotyping, including tissue-specific profiling, may be
an important future area to identify individuals or sub-
groups that benefit or do not benefit from increased dairy
consumption (11).
The evidence from available prospective cohort studies
and RCTs has both strengths and also weaknesses (106).
Most prospective cohort studies have investigated risk
factors in large populations with long follow-up periods,
but one can never exclude residual confounding in cohort
studies. The approach of Mendelian Randomization is
recognized as a useful approach in epidemiological studies
to demonstrate strong evidence of causality between diet and
disease outcomes. To our knowledge, very few Mendelian
Randomization studies have been done to investigate the
association between dairy consumption and T2D risk, and
the genes used are milk related and not yogurt or cheese
related. For example, lactase gene (LCT-139010 C/T) was
used by the study of Bergholdt et al. (43) to investigate
dairy consumption and T2D risk; however, fermented dairy
products (e.g., cheese and yogurt) have a lower content of
lactose than milk, thus, using a lactase gene to examine
the association between fermented dairy products and T2D
risk may result in underestimated results. In addition,
because the effect of confounding factors is always an issue
of concern in nutritional epidemiology, comparisons of
dairy products with other foods should be investigated in
replacement models to take into account the background
diet; however, this type of research is still very limited
(21, 97, 98).
Although RCTs have the advantage of ruling out residual
confounding factors to provide robust evidence for causality
between diet and risk factors compared with prospective
cohort studies, the available RCTs are generally limited to
short intervention times which may not be sufficient to
assess the full effect of dairy foods on glucose homeostasis.
Also, it is unlikely to have RCTs with hard endpoints
of incident T2D (57), thus, further mechanistic studies
combined with large prospective studies with replacement
models, and large RCTs in adequate populations (metabol-
ically unhealthy/healthy) of sufficient dose and duration are
needed to get a complete picture of dairy consumption and
T2D risk.
Overall Conclusions/Public Health Relevance
and Possible Impact for Public Health
Recommendations
Based on the reviewed evidence, epidemiological data and
RCTs suggest that there is a neutral or moderate inverse
association between dairy consumption andT2D risk. Yogurt
was especially associated with a lower T2D risk. Therefore,
more and better data from epidemiological studies and RCTs
are needed on the impact of dairy consumption on glucose
homeostasis. Specifically, there are several key research
questions that need to be answered to optimize the benefits
of dairy consumption and to close the gaps in the existing
knowledge:
1) How does an individual’s phenotypic status, such as
age, sex, weight, disease status, metabolic status, and
gut microbiota composition, affect their glucoregulatory
responses to different types of dairy consumption?
2) How does high-/low-fat, high-/low-sugar, high-/low-
protein dairy affect T2D risk?
3) What are the underlying mechanisms that explain the
inverse association between yogurt and T2D risk?
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